Companies: 10,795·Total market cap: $144.5T
Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc.

CYTNASDAQHealthcare
$3.02
$-0.07(-2.27%)
Market Cap$108714262
P/E Ratio
52W High$3.19
52W Low$1.65

Cyteir Therapeutics, Inc. (CYT) Revenue

Annual & quarterly revenue history · segment & region breakdown

CYT · revenue · updated Jun 10, 2026

Core revenue metrics

Cyteir Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
46 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Cyteir Therapeutics, Inc. SEC filings · GAAPUpdated: 2026-06-10

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
CYT revenue by year · CYT revenue history · CYT annual revenue data

Compare revenue vs peers

Biotechnology

Compare CYT revenue against listed peers. Click any row to open that company's revenue tab.

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Cyteir Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Cyteir Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Cyteir Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

CYT revenue · 4 questions

CYT's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

CYT revenueCYT annual revenuewhat is CYT revenueCYT TTM revenue

Source: FMP · Cyteir Therapeutics, Inc. SEC filings · GAAP · Cyteir Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026